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Abstract
Objective: The antigen, falciparum malaria protein 1 (FMP1), represents the 42-kDa C-terminal fragment of merozoite
surface protein-1 (MSP-1) of the 3D7 clone of P. falciparum. Formulated with AS02 (a proprietary Adjuvant System), it
constitutes the FMP1/AS02 candidate malaria vaccine. We evaluated this vaccine’s safety, immunogenicity, and efficacy in
African children.
Methods: A randomised, double-blind, Phase IIb, comparator-controlled trial.The trial was conducted in 13 field stations of
one mile radii within Kombewa Division, Nyanza Province, Western Kenya, an area of holoendemic transmission of P.
falciparum. We enrolled 400 children aged 12–47 months in general good health.Children were randomised in a 1:1 fashion
to receive either FMP1/AS02 (50 mg) or RabipurH rabies vaccine. Vaccinations were administered on a 0, 1, and 2 month
schedule. The primary study endpoint was time to first clinical episode of P. falciparum malaria (temperature $37.5uC with
asexual parasitaemia of $50,000 parasites/mL of blood) occurring between 14 days and six months after a third dose. Case
detection was both active and passive. Safety and immunogenicity were evaluated for eight months after first
immunisations; vaccine efficacy (VE) was measured over a six-month period following third vaccinations.
Results: 374 of 400 children received all three doses and completed six months of follow-up. FMP1/AS02 had a good safety
profile and was well-tolerated but more reactogenic than the comparator. Geometric mean anti-MSP-142 antibody
concentrations increased from1.3 mg/mL to 27.3 mg/mL in the FMP1/AS02 recipients, but were unchanged in controls. 97
children in the FMP1/AS02 group and 98 controls had a primary endpoint episode. Overall VE was 5.1% (95% CI: 226% to
+28%; p-value=0.7).
Conclusions: FMP1/AS02 is not a promising candidate for further development as a monovalent malaria vaccine. Future
MSP-142 vaccine development should focus on other formulations and antigen constructs.
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Plasmodium falciparum malaria kills over one million children
annually in sub-Saharan Africa [1] where it is considered both a
cause and a consequence of poverty [2]. In the last decade several
malaria vaccine candidates have progressed to clinical evaluation
[3]. RTS,S/AS02, a pre-erythrocytic stage falciparum malaria
vaccine, showed reductions of 35% for clinical disease and 49%
for severe disease over an 18 months follow up period, in one to
four year old Mozambican children [4,5], confirming the
feasibility of malaria vaccines and their potential to impact the
burden of disease in infants.
A second promising P. falciparum vaccine target is the blood stage
antigen merozoite surface protein-1 (MSP-1) [6,7]. This abundant
merozoite membrane surface protein undergoes a series of
processing steps, with the final cleavage of the C-terminal p42-
kDa portion of the molecule into p33-kDa and p19-kDa molecules
required for erythrocyte invasion [8]. Monoclonal antibodies that
specifically interfere with this cleavage can inhibit parasite invasion
[9]. Epidemiologic studies have shown that antibodies directed
against this part of MSP-1 are associated with protection
[10,11,12]. Aotus monkeys vaccinated with MSP-142 have been
protected from P. falciparum challenge [13,14] and antibodies
derived from such animals have exhibited in vitro growth inhibition
activity [15]. A previous study of MSP1 and MSP2 recombinant
proteins combination malaria vaccine candidate (Combination B)
showed a significant reduction in parasite density in the vaccinated
group but no significant effect on clinical episodes [16]. However,
multiple inoculations with subinfective doses of whole cell infected
cryopreserved erythrocuytes followed by immediate antimalarial
treatment conferred T cell mediated protection against infection in
a challenge study [17].
MSP-142 from the 3D7 clone of P. falciparum was expressed in
Escherichia coli. The final product, designated falciparum malaria
protein 1 (FMP1) [18], has been formulated with GlaxoSmithK-
line Biologicals’ (GSK) proprietary Adjuvant System AS02. Earlier
studies showed the FMP1/AS02 formulation to be safe and
immunogenic in rhesus monkeys [19] and in adult humans in the
United States [20], Kenya [21], and Mali [22]. Subsequently, a
Phase Ib dose-escalating trial demonstrated its safety and
immunogenicity in 12 to 47 month old Kenyan children [23].
The 50 mg dose gave a 16-fold rise in the geometric mean titre
(GMT) of anti-MSP-142 antibodies from baseline to one month
after a third vaccination. These encouraging results led to the
present proof-of-concept efficacy trial in the same population,
which is the first to evaluate monovalent MSP-142 for efficacy in a
field setting.
Methods
The protocol for this trial and the supporting CONSORT
checklist are available as supporting information; Checklist S1 and
Protocol S1.
Study site
The study was conducted at the KEMRI-‘‘Walter Reed
Project’’ (WRP) Kombewa Clinic (KC) in the Kombewa Division
of Kisumu District of Nyanza Province in western Kenya, an area
of hyperendemic malaria transmission with peaks during the long
rains (March–June) and short rains (November–December). The
study population, almost exclusively of the Luo tribe, predomi-
nantly Seme sub-tribe, was drawn from one mile radius catchment
areas around each of 13 field stations. The field stations were
staffed 24 hours/day throughout the study period to facilitate
medical care. P. falciparum accounts for more than 95% of the
malaria infections [24] with mosquitoes of the Anopheles gambiae
complex being the major vector [25] with an EIR of 0.65–0.79
infectious bites per person per night [24,25].
Participants
Demographic surveillance was conducted at the Kombewa
Division field stations in 2003–2004. During the census, the
families with children aged 12–47 months were identified and
homesteads located in relation to the field stations. At the time of
the study initiation, parents/guardians were invited to come to the
KC for briefing and those who gave consent were later requested
to bring their children to the KC for eligibility screening. Children
were excluded according to the same criteria used in the previous
paediatric Phase Ib study [21], except for the slight modifications
of serum alanine aminotransferase (ALT) of $45 IU/L and
absolute lymphocyte counts (ALC) for one-year olds of ,4.0610
3/
mm
3, for two-year olds of ,3.0610
3/mm
3, and for three-year olds
of ,2.0610
3/mm
3.
Groups that approved the study protocol were: Kenya Medical
Research Institute (KEMRI) Scientific Steering Committee and
Ethical Review Committee, Walter Reed Army Institute of
Research (WRAIR) Scientific Review Committee, US Army
Medical Research and Materiel Command (USAMRMC),
Human Subjects Research Review Board (HSRRB), and the
PATH Human Subject Protection Committee (HSPC). The
United States Food and Drug Administration (FDA) reviewed
the protocol. The study was conducted in accordance with the
International Conference on Harmonisation Guideline for Good
Clinical Practice. Pharmaceutical Product Development, Inc.
(PPD) and the US Army Medical Materiel Development Activity
(USAMMDA) monitored the study. An independent Local
Medical Monitor (LMM) and a data and safety monitoring board
(DSMB) closely reviewed the trial’s progress.
Procedures
Before recruiting study participants, representatives of the study
team met with local chiefs and community leaders to describe the
study. Field workers then visited individual homesteads known to
have potential study participants and invited the parents or
guardians to visit the clinic for recruitment briefings. At each
briefing session parents/guardians received a copy of the informed
consent form (ICF). Groups watched a videotape detailing (in the
Luo language) the study and information on the ICF, which was
followed by a public question and answer session. Parents/
guardians were then invited for private individual discussions with
a study physician assistant or study nurse, after which they were
invited to sign (or thumb print if illiterate) the ICF. For each
illiterate parent/guardian, an impartial member of the community
countersigned as a witness.
During the screening visits, within 45 days before the first
immunisation, the children had a detailed clinical history, physical
examination, and blood sampling for haematology and biochem-
istry evaluations. The children were randomised on day 0 and
received the vaccine on days 0, 29 (69) and 57 (69). After each
vaccination the children were evaluated for solicited adverse
events (AEs) on days 0, 1, 2, 3, and 6. The unsolicited AE follow-
up periods ran for 30 days (vaccination days and the subsequent 29
days). Serious adverse events (SAEs) were reported throughout the
duration of the study. During the efficacy follow-up period, all
SAEs were reported within 24 hours of occurrence. In the event
that a child was treated outside the WRP KC or the New Nyanza
Provincial General Hospital copies of all available clinical records
of the encounter were obtained, reviewed and maintained in the
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member of the clinical team visited the subject at least once daily
and reported to the principal investigator (PI) or his designee. The
PI remained in contact with the paediatrician or any other medical
specialist who provided care to the subject to ensure that the
locally appropriate medical care was provided.
During the follow-up period, clinical malaria cases were tracked
and parasite densities and immunogenicity measured. Surveillance
was performed on a biweekly basis through monthly field worker
home visits and monthly clinic visits (window period: 67 days)
(i.e., the clinic and home visits were staggered 2 weeks apart hence
the child was seen twice per month). During the home visits to the
children field workers documented axillary temperatures, solicited
history of fever in the previous 24 hours and of any concomitant
medications taken, and reminded parents/guardians of future
appointments and the necessity of bringing sick children to the
KC. Children with a fever or history of fever in the past 24 hours
were taken to the KC for evaluation, including malaria blood films
(MBFs) and complete blood counts (CBCs). Out-migrations,
absences from Kombewa Division, and antimalarial drugs usage
were documented.
Clinic and home visits were staggered so that each child was
evaluated (active detection) about every fortnight. During the
clinic visits, an interim history and an axillary temperature were
obtained, a history-directed clinical examination was performed,
and blood was drawn (Figure 1).
Clinical malaria was also identified by passive detection (when ill
children presented to the KC or to field stations). Blood samples for
CBC and MBF were obtained whenever an illchild presented to the
clinic. At study start, parents were advised to seek medical attention
for the children exclusively at the KC whenever possible Children
requiring inpatient care were admitted to the NNPGH. Uncom-
plicated malaria was treated with a 6 dose course of artemether/
lumefantrine (CoartemH) and quinine in case of severe malaria.
Laboratory procedures. Two microscopists independently
read Giemsa-stained thin and thick malaria blood films (MBFs)
and quantified them according to a standard operating procedure.
Results were double data entered into a laboratory database; a
third, more experienced reader resolved any discordant
microscopy findings. Parasite densities were calculated against
same-day CBCs.
Induction of humoral immunity was measured with an enzyme-
linked immunosorbent assay (ELISA) using purified bulk FMP1
(MSP-142 3D7) as the capture antigen [20]. Results are reported in
mg/mL, derived by comparison to a defined standard [26]. The
KEMRI/‘‘WRP’’ Kondele unit Laboratory in Kisumu performed
the ELISA analysis and associated quality control assays;
additional quality control analyses were performed at the Malaria
Serology Laboratory, WRAIR, USA.
Interventions
Vaccines. The FMP1 antigen, described in detail elsewhere
[20], was manufactured according to current Good
Manufacturing Practices (cGMP) at the WRAIR pilot
Bioproduction facility in Silver Spring, MD, USA. The AS02
Adjuvant System, manufactured by GSK Biologicals, contains an
oil-in-water emulsion and components also described elsewhere
[20]. A vial containing the lyophilised 60 mg FMP1 pellet was
reconstituted in 0.6 mL of AS02 and, after mixing, a syringe
containing 0.5 mL was prepared for injection. The vaccine was
administered immediately after reconstitution. The comparator
group received the licensed rabies vaccine RabipurH (manufactured
in India by Chiron Behring Vaccines Pvt, Ltd) supplied in single
dose vials containing lyophilised antigen with 1.0 mL of diluent
(sterile water) for injection.
Vaccine administration. After confirming eligibility, staff
drew blood for laboratory tests. The pharmacy team confirmed
individual assignments to vaccine groups and then prepared the
appropriate vaccine. Because the vaccines differed in volume and
appearance, the pharmacy team masked the barrel of the syringe,
labeled the syringe with each individual’s unique randomisation
code and study ID number, and passed the syringe through a small
service hatch into the vaccination room.
A vaccine administration team confirmed each child’s identity,
study number, and randomisation code before administering
vaccine. A nurse administered the vaccine by slow intramuscular
injection into the left anterolateral thigh. Vaccinations were
performed on a 0, 1, and 2 month schedule (Figure 1). The nurses
administering the vaccine were not involved in the post-
vaccination assessments.
Post-vaccination procedures. Children were observed for
60 minutes after each vaccination. Parents/guardians were
instructed to return with children to the KC immediately for any
new symptoms. The study team evaluated the children on days 1, 2,
3, and 6 after each vaccination to collect solicited (pain, swelling,
fever, irritability/fussiness, loss of appetite, and drowsiness) and
unsolicited AEs. If a parent and child did not appear for a scheduled
clinic visit, a clinician or nurse visited them on the same day to
measure vital signs and collect information on any AEs that
occurred during the previous 24 hours. Transportation was
provided for the participants to KC, where AEs were evaluated,
monitored, and clinically managed until resolution.
Objectives
The primary objective was to evaluate the vaccine efficacy (VE)
against first clinical episodes of P. falciparum malaria over a six
month period commencing 14 days after a third vaccination.
Clinical malaria for the primary endpoint was defined as parasite
density $50,000 parasites/mL n the presence of fever (axillary
Figure 1. Schematic of trial profile.
doi:10.1371/journal.pone.0004708.g001
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unpublished epidemiology study in children of the same group
prior to the study.
Secondary objectives were to evaluate: (1) clinical episodes of P.
falciparum malaria using alternate case definitions; (2) parasite
density; (3) safety as evaluated by solicited adverse events (AEs)
occurring in the week following each vaccination, unsolicited AEs
occurring within 30 days of each vaccination, serious adverse
events (SAEs) occurring throughout the study, and time to
anaemia (Hb,8.0 g/dL); (4) immunogenicity as assessed by
geometric means of anti-MSP-142 antibody concentration
throughout the study; (5) the immunogenicity from first vaccina-
tion through the end of the follow-up period; and (6) association
between anti-MSP-142 antibody concentration and the subsequent
risk of clinical malaria during the follow-up period.
Outcomes
Assessment of primary outcome. The primary outcome
was designated as time to first clinical episode of P. falciparum
malaria meeting the ‘‘Primary Case Definition’’ (Table 1) during
the six month efficacy follow-up period. Time was measured from
14 days after administration of a third dose of study vaccine. The
logrank statistic and corresponding p-value was calculated to test
the null hypothesis of no difference in the distribution of time to
clinical malaria between the FMP1/AS02 and rabies vaccine
groups. A Cox proportional hazards model with an indicator
variable for vaccine group was fit to the data and an estimate of
the hazard ratio along with its corresponding 95% confidence
interval was computed. VE was defined as one minus the hazard
ratio. Additional Cox models explored the effects of age, sex, bed
net use as reported at baseline, nearest field station, and
haemoglobin genotype on vaccine efficacy. Kaplan-Meier curves
for time to clinical malaria were generated by vaccine group. An
alternative estimate of VE based on cumulative incidence rates
was calculated as well. The primary data analysis was conducted
with the according-to-protocol cohort; however, a similar analysis
based on the intention-to-treat cohort was also performed to assess
the robustness of the analysis based on the according-to-protocol
cohort.
Assessment of secondary outcomes. The purpose of the
secondary outcomes was to gain further insight into the efficacy of
the vaccine and to help define a primary endpoint for a future,
confirmatory Phase III trial. These were not intended for use to
make formal claims about the vaccine. Other secondary endpoints
assessed safety and immunogenicity of the vaccine. Similar
analyses as those outlined for the primary endpoint were carried
out for the following endpoints.
Measurements of efficacy included (1) time to clinical episode of
P. falciparum malaria meeting the various secondary case definitions
(Table 1); (2) time to presence of asexual stage P. falciparum
parasites; (3) time to parasite density $50,000 asexual stage P.
falciparum parasites/mL of blood; (4) number of clinical episodes of
malaria, per subject, meeting the primary case definition; statistical
methods for recurrent event data, such as Poisson regression, were
used to assess the effect of FMP1/AS02 vaccination on the average
number of clinical episodes per subject; (5) time to anaemia
(defined as Hb,8.0 g/dl, whether by active or passive case
detection); (6) proportion of children with anaemia.
Assessment of safety included (1) occurrences of solicited AEs
during a seven-day follow-up period after each vaccination; (2)
occurrences of unsolicited AEs during a 30-day follow-up period
after each vaccination; and (3) occurrences of SAEs between the
first vaccination and the end of the follow-up period. Assessment of
immunogenicity included geometric means of anti-MSP-1 titers at
Table 1. Malaria case definitions and vaccine efficacy in the according-to-protocol group.
Clinical Malaria
Malaria Definitions Vaccine Efficacy
Case Definition Fever
a
Parasite
density
b
FMP1/AS02
(N=195)
RabipurH
(N=190)
Vaccine
efficacy
95% confidence
interval p-value
Secondary (200) $37.5uC AND
c $200 K 44 40 26.8 (264, 30) 0.8
Secondary (100) $37.5uC AND $100 K 75 75 1.6 (236, 29) 0.9
Primary $37.5uC AND $50 K 97 98 5.1 (226, 28) 0.7
Secondary (10) $37.5uC AND $10 K 106 108 6.5 (222, 29) 0.6
Secondary (0) $37.5uC AND .0 132 138 12.3 (211, 31) 0.3
Secondary (0
*) $37.5uC OR history of
fever
AND .0 173 168 5.3 (217, 23) 0.6
Malaria Infection (Symptomatic or Asymptomatic)**
Malaria Definitions Vaccine Efficacy
Case Definition Parasite density FMP1/AS02 RabipurH Vaccine efficacy
95% confidence
interval p-value
Infection definition Parasite density .0 173 [192] 170 [184] 7.7 (214, 25) 0.5
Infection definition (50) Parasite density $50 K 128 [190] 128 [183] 12.5 (212, 32) 0.3
*History of fever within the last 24 hours.
**Children who met these infection endpoints on the first day of the efficacy follow-up period were excluded from these analyses. Numbers of children at risk are shown
in brackets.
aFever is documented by axillary temperature.
bAsexual stage P. falciparum parasites/ml blood; K denotes thousands.
cAND means ‘‘simultaneous presence of.’’
doi:10.1371/journal.pone.0004708.t001
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after the third vaccination.
Sample size
A year-long (2003–4) longitudinal cohort study in the same area
showed monthly clinical malaria attack rates of between 20% and
55% in children aged one to three years (unpublished data). The
sample size calculation for this trial assumed a 50% attack rate
over the six-month follow-up period with time to clinical malaria
following an exponential distribution. A trial with 200 children per
study arm would have 80% power to detect a 30% reduction in
the six-month cumulative incidence rate.
Randomisation—sequence generation, allocation
concealment, implementation
A randomisation list containing sequential codes linked to a
study vaccine assignment was computer generated in the USA by
Statistics Collaborative, Inc. These codes were assigned to
participants in the order in which they presented to the clinic on
the day of first vaccination. The code was then supplied to the
study drug manager and the site pharmacist, who were responsible
for randomising the study participants. Randomisation was
performed within blocks of eight. Each randomisation assignment
was sealed in a unique, tamper-evident envelope, which was
opened at the time a subject presented for the first vaccination. At
the end of every vaccination day, the randomisation list was
secured in a locked safe accessible only to the study drug manager,
the pharmacist, and the pharmacist’s assistants. The only other
person in Kenya who had access to the randomisation code at the
study site was the LMM for use in case emergency unblinding
became necessary for safety purposes. Four hundred children were
randomised in the order of presentation to the clinic on the days of
first vaccination; 200 received FMP1/AS02 and 200 RabipurH
rabies vaccine.
Blinding
At the study site, only the pharmacist, pharmacy assistant and
the drug manager were aware of the randomisation codes of the
children. Children, parents, investigators, lab personnel and all
staff performing follow-up evaluations were blinded as to vaccine
assignment. Because the color and volumes of the reconstituted
FMP1/AS02 and comparator vaccines differed, the barrel of the
syringe was covered with opaque tape to mask its contents and
labeled with the subject identification number and randomisation
code. Children, parents, and the staff performing follow-up
evaluations were all blinded. Vaccinations were carried out
simultaneously in four separate consultation rooms, which were
connected to a central pharmacy (the vaccine preparation room)
by small, closable service hatches. On vaccination days, the
prepared syringe was handed through a service hatch to a
vaccinator for vaccine administration. For each subject, an
identification number, a randomisation code from a chart, and a
randomisation code on the syringe were recorded on a vaccination
form. Following vaccine administration, children were assessed
and follow-up visits conducted by a group of clinicians who had
not been involved in the vaccinations.
Statistical analysis
Data were recorded on case report forms that underwent 100%
verification by a quality assurance team before double data entry
into a SQL Server 2000H database. The database also underwent
100% verification by a quality assurance team before the archiving
and transmission to the statisticians. Data analysis was performed
on the locked database using SAS (version 9.1) and S-Plus (version
6.2) according to a prewritten statistical analysis plan.
The according-to-protocol cohort included all children who
received the three vaccinations and had no significant protocol
violation. Analyses of efficacy were based on the according-to-
protocol cohort, counting each subject’s first malaria case that
emerged at least 14 days after a third vaccination to the end of the
follow-up period. The intention-to-treat cohort included all
randomised children. Supportive analyses, based on the inten-
tion-to-treat cohort, counted all cases that emerged from the day
of first vaccination.
The primary endpoint was analyzed with a logrank test. A Cox
proportional hazards model (SAS Proc PHREG) was used to
estimate the hazard ratio along with its corresponding 95%
confidence interval: VE is one minus the hazard ratio. Similar
analyses were performed for other case definitions. Additional Cox
models explored the effects of age, sex, baseline bednet use, field
station location, and haemoglobin genotype on VE. Kaplan-Meier
curves displayed time to event. An alternative estimate of VE
based on cumulative incidence rates, excluding time periods when
the subject was not at risk for contracting a new case of malaria,
was calculated using Poisson regression. Fisher’s Exact Test
compared binary variables. Parameters measuring immune
response were calculated and compared between groups using
longitudinal models (SAS Proc MIXED) with a spatial power
covariance structure.
Results
Participant flow
A total of 625 children between 12 and 47 months of age were
screened, 535 were deemed eligible, and 400 were randomised,
200 to each of the two vaccine groups (Figure 2). Compliance and
retention rates were high: 385 of the 400 children (96%)
completed the six months of follow-up and at least 95% of
children attended each of the nine scheduled clinic visits.
Recruitment
Study enrolment/randomisation, vaccination, and follow-up
were conducted from March 2005 to December 2005.
Baseline data
At baseline, the two groups were similar (Table 2) and within
each field station (data not shown). The baseline clinical laboratory
parameters were within normal range.
Numbers analyzed
A total of 374 (191 FMP1/AS02 and 183 in the comparator)
children who completed the study as per the protocol were
included in the according-to-protocol analysis.
Outcomes estimation
Vaccine efficacy. VE was determined for the 385 children
who met all criteria for the primary efficacy analysis (Table 1); 195
children—98 in the RabipurH group and 97 in the FMP1/AS02
group—experienced at least one case of P. falciparum malaria
meeting the primary case definition. Estimated VE was 5.1% (95%
CI: 226% to +28%; p-value=0.7). The two groups had similar
distributions of time to malaria following a third vaccination and
were essentially identical throughout the period of observation
(Figure 3). The according-to-protocol curves for the first 71 days,
by definition, remain at 100% because cases occurring in this
period do not contribute to the primary efficacy analysis.
Malaria Vaccine Trial
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that of the primary (Table 1). Moreover, according-to-protocol
analysis of monthly cross-sectional surveys during the efficacy
follow-up period showed similar proportions of children with
parasitaemia and similar distributions of parasite density in the two
vaccine groups.
The rate of disease meeting the primary case definition per
person year was 1.70 in the FMP1/AS02 group and 1.76 in the
RabipurH group (p-value for Poisson regression=0.8). Thus, no
significant difference between arms was observed with respect to
the number of clinical episodes per subject meeting the primary
case definition. The intention-to-treat analysis showed 122 and
Figure 2. Trial profile.
doi:10.1371/journal.pone.0004708.g002
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ly, for a VE of 15% (95% CI: 29% to 34%; p-value=0.2). Active
case detection identified 16% and 12% of the FMP1/AS02 and
comparator groups, respectively. The comparable proportions in
the according-to-protocol group were 23% and 28%.
Ancillary analyses
We performed some exploratory, subgroup analyses that were
not pre-specified. The following nominal p-values, not corrected
for multiplicity, reflect the results of tests measuring whether the
effect of vaccine differed by subgroup. At screening, parents were
asked, ‘‘Does your child always sleep under a mosquito net at
home?’’ VE in the two-thirds of the children (n=288) reportedly
always using bednets at baseline was 220% (p=0.3) versus 48%
(p=0.017) in non-bednet users (interaction p-value=0.009). VE
did not differ as a function of age (p=0.7); sex (p=0.1); erythrocyte
abnormalities (sickle cell trait, glucose 6-phosphate dehydrogenase
deficiency (G6PD), or alpha-thalassemia; p=0.7); presence of
parasitaemia at baseline (p=0.4); or anti-MSP-142 antibody level
either at baseline (p=0.1) or at day 85 (p=0.3).
We evaluated the possible impact of treatment with artemether/
lumefantrine on the according-to-protocol time to clinical episodes
before and after day 71 using several types of analyses. However,
every analysis resulted in the same outcome, confirming to us the
robustness of the results. Some of the exploratory analyses
included: (i) time to first event starting at Day 0 (intention-to-
treat) using various density cutoffs,(ii) time to first event starting at
14 days after Immnusation. 3 (according-to-protocol) using various
density cutoffs, (iii) intention-to-treat and according-to-protocol
analyses adjusted for time not at risk due to malaria treatment, and
(iv) Poisson regression (intention-to-treat and according-to-proto-
col), where children were considered not at risk for 7 or 28 days
following each new clinical case of malaria if they were treated
with quinine or artemether/lumefantrine respectively.
In the summer of 2007, after all statistical analyses had been
completed, we reviewed the distribution of parasite densities and
found an unexpected bimodality. The distribution dipped between
modes straddling the density range where microscopists switched
from thick to thin film reading according to their standard
operating procedures; the modes also straddled the primary
efficacy endpoint cutoff, 50,000 parasites/mL.
We subsequently reread 643 pairs of films from all febrile
episodes of malaria with parasitemia greater than 10,000
parasites/mL (618 pairs) and a random sample of episodes with
densities less than 10,000 parasites/mL (25 pairs). For this
rereading, each of two microscopists read both thin and thick
films from the same malaria episode. If either of the pairs of thick
or thin film readings yielded discordant results, a third, expert
reader performed a tie-breaking read on both types of films.
The goal of the reread was to reevaluate our conclusions
concerning the efficacy of the vaccine. Although the original reads
performed during the course of the trial and the rereads performed
in 2007 showed some discordance, and the point estimates of the
various measures of efficacy changed modestly, the qualitative
conclusions remained unchanged.
Immunogenicity
The concentration of MSP-142-specific antibodies, as measured
by ELISA (Figure 4), rose rapidly after each immunisation with
FMP1/AS02, but declined slightly over time in the comparator
group. Post-baseline geometric mean antibody concentrations
were significantly different (p,0.0001). The highest concentration
was observed on study day 85, approximately four weeks after
third immunisations. At this time, the geometric mean antibody
concentration in vaccine recipients was 26.3 mg/mL, compared
with 1.3 mg/mL in the same group before vaccination, and
1.4 mg/mL in the comparator group at day 85 (p,0.0001). The
antibody levels in vaccinees declined subsequently over time, but
did not reach their prior baseline values during this follow-up
period. Antibody response did not differ according to age when
one-, two- and three-year-olds were compared by a longitudinal
repeated measures analysis (p=0.3). However, there was no
association between peak (day 85) antibody response and time to
first case of malaria (p=0.33).
Adverse events
Both FMP1/AS02 and the comparator vaccine had a good
safety profile and were well tolerated. The FMP1/ AS02 group
had more local (88% versus 8%) and vaccine-related, systemic
(61% versus 16%) solicited reactions. More grade 3 AEs occurred
in the FMP1/AS02 group; the majority were injection site pain or
fever (Table 3) mostly resolving within 48 hours. In both groups,
the frequency and severity of solicited AEs decreased with
subsequent vaccinations (not shown).
In each group, 197 individuals experienced at least one
unsolicited AE during the 30 days following vaccination. The
most common, malaria, upper respiratory tract infection, skin
disorders, and diarrhoea, were evenly distributed between the two
vaccine groups.
Table 2. Demographic, clinical, and laboratory baseline
characteristics of 400 randomised children prior to first
vaccination.
Characteristics
FMP
1/AS02 RabipurH
N=200 N=200
Mean age in months6SD 29.6610.1 30.069.9
No. male (%) 101 (51%) 118 (59%)
Mean height in cms6SD 84.868.0 85.168.3
Mean weight in kgs6SD 11.962.5 12.062.4
No. always using bednets (%) 142 (71%) 146 (73%)
No. with sickle cell trait (%) 36 (18%) 42 (21%)
No. G6PD deficient (%) 24 (12%) 25 (13%)
No. alpha-thalassemia homozygous (%) 22 (11%) 15 (8%)
No. alpha-thalassemia heterozygous (%) 80 (40%) 98 (49%)
No. parasitemic (%) 60 (30%) 56 (28%)
Median parasite density (75
th percentile) 0 (440) 0 (400)
Mean WBC 610
3/mL6SD 9.663.0 9.662.9
Mean Hb g/dL6SD 10.461.2 10.361.2
Mean platelets 610
3/mL6SD 3266121 3246112
Mean lymphocyte count 610
3/mL6SD 5.562.0 5.562.0
Mean creatinine Mm/L6SD 39.5614.6 38.7615.4
Mean ALT U/L6SD 12.468.6 13.3611.0
GM anti-MSP-142 antibody concentration
(mg/mL)
1.34 1.53
Median anti-MSP-142 antibody
concentration (25
th,7 5
th percentiles)
1.6 (0.4, 7.7) 1.5 (0.4, 6.4)
ALT, alanine aminotransferase; G6PD, glucose-6-phosphate dehydrogenase
deficiency; GM, Geometric mean; Hb, haemoglobin; SD, standard deviation;
WBC, white blood cell.
doi:10.1371/journal.pone.0004708.t002
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doi:10.1371/journal.pone.0004708.g003
Figure 4. Geometric mean anti-MSP-142 antibody concentrations estimated from the model, log10-transformed.
doi:10.1371/journal.pone.0004708.g004
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RBC, PLT, ALC, ALT, and Cr) were similar between the two
groups and remained unchanged from baseline (not shown).
Mean haemoglobin values rose in both groups throughout the
study (10.5 g/dL to 11.1 g/dL for FMP1/AS02; 10.3 g/dL to
10.9 g/dL for RabipurH). Both groups included individuals who
had episodic, transient low haemoglobin values (standard range:
6.5–13.0 g/dL) (nine individuals in FMP1/AS02; two individual
in RabipurH group) that returned to normal without transfusion.
Additionally, one case of severe anaemia (Hb,5.0 g/dL) associ-
ated with severe malaria occurred in each vaccine group. In the
intention-to-treat cohort, time to first episode of Hb,8.0 g/dL did
not differ statistically between the groups (logrank p-value=0.11;
Hazard ratio=1.53, 95% CI: 0.90–2.59).
Serious adverse events
Serious and unexpected AEs were collected throughout the
study. No reported SAE was judged related to vaccination.
Twenty-six SAEs occurred in 23 children: 15 in the FMP1/AS02
group and 8 in the RabipurH group. Fourteen of these SAEs were
severe malaria cases, consistent with the 2000 World Health
Organization criteria [27]. Nine of these severe malaria cases
occurred in the FMP1/ AS02 group (cerebral malaria with
anaemia,5.0 g/dL=1, respiratory distress and prostration=1,
multiple convulsions=1, parasitaemia$20%=3, respiratory dis-
tress=3); five occurred in the RabipurH group (anaemia,5.0 g/
dL=1, multiple convulsions=1, parasitaemia$20%=2 instances
in 1 subject, respiratory distress=1).
A 15 month old male in the comparator group presented with
malaria 24 days after his third vaccination, developed severe
anaemia four days into antimalarial treatment, and died 38 days
later. The child was hospitalised and transfused several times for a
recurrent Coombs negative, haemolytic anaemia that was
refractory to transfusion. No haemoglobinopathy was identified;
however, three of his brothers had died of anaemia in early
childhood. Autopsy found no specific aetiology.
Discussion
Interpretation
The FMP1/AS02 vaccine did not protect children living in
Kombewa against first episodes of P. falciparum malaria; it did not
reduce the overall incidences of clinical malaria episodes or of
malaria infections, and did not reduce parasite densities (Table 1).
The agreement between the according-to-protocol and the
intention-to-treat efficacy analyses strengthens these findings. This
corroborates the observation of no significant effect on clinical
episodes in the combination B study [16].
The reasons for the lack of efficacy are unclear. The study had
adequate power to detect VE of clinical importance. In malaria-
naı ¨ve adults in the United States, FMP1/AS02 induced high titre,
functional antibodies that recognised P. falciparum merozoites by
indirect fluorescent antibody (IFA) and exhibited in vitro growth
inhibitory activity [20]. Concurrent potency and stability testing of
the final product showed no change over time. VE was not
associated with age.
Active and passive case detection was intense and sustained, so
that undetected cases of clinical malaria would be unlikely. It is
also unlikely that the frequent active follow-up and aggressive
treatment of malaria pursued as part of the study design prevented
the detection of VE, because majority of the proportions of
endpoint cases in both groups resulted from passive case detection
alone (77% and 72% in FMP1/AS02 and RabipurH recipients,
respectively). The parasite reduction effect reported with MSP
combination B vaccine candidate [16] as a possible surrogate for
protection was not seen in our study.
Although FMP1/AS02 elicited a greater MSP-142–specific
immune response than did the comparator vaccine, this response
was not a surrogate marker of protection. This is underscored by
the results of the (albeit unscheduled and statistically insignificant)
analysis for VE as a function of age; the youngest children,
although mounting the highest antibody responses, showed no
difference in protection from their older counterparts. Similarly,
there was no association between peak (day 85) antibody response
and time to first case of malaria (p=0.33). The absence of
relationship between MSP-142–specific antibody levels and VE
observed here contrasts with the positive correlation of anti-MSP-
142 antibodies with protection described in epidemiologic studies
based on the Camp/FUP allele of MSP-142 [28,29].
The lack of observable VE has several hypothetical explana-
tions. Owing to the high multiplicity of infection and the diversity
of MSP-142 phenotypes in Kenya (unpublished data), immunity
conferred by the study vaccine may be directed to a minor parasite
Table 3. Number of children with at least one solicited adverse event up to seven days following any vaccination.
Grade 3 AE Any AE
FMP1/AS02 RabipurH p-value FMP1/AS02 RabipurH p-value
(n=200) (n=200) (n=200) (n=200)
All adverse events 33 (17) 7 (4) ,0.001 195 (98) 85 (43) ,0.001
Local (injection site)
Pain 18 (9) 0 (0) ,0.001 175 (88) 14 (7) ,0.001
Swelling 3 (2) 0 (0) 0.25 80 (40) 2 (1) ,0.001
General (systemic)
Fever 13 (7) 4 (2) 0.044 135 (68) 61 (31) ,0.001
Drowsiness 0 (0) 0 (0) 1.00 2 (1) 0 (0) 0.50
Loss of appetite 5 (3) 2 (1) 0.45 67 (34) 30 (15) ,0.001
Irritability/fussiness 0 (0) 1 (1) 1.00 26 (13) 2 (1) ,0.001
*Grade 3 AE=An adverse event that prevents normal, everyday activities: for pain=cries when limb is moved or spontaneously painful or limping or reluctance to bear
weight; for swelling=.20 mm; for fever=.39.0uC. (No event was of higher severity than Grade 3.)
P-values are based on Fishers Exact Test.
doi:10.1371/journal.pone.0004708.t003
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specificity of the response may correlate best with protective
immunity [12,14]. Ongoing studies are investigating antibody fine-
specificity. Of particular interest will be the investigation of the
induction of antibodies that compete with specificities previously
shown to inhibit parasite invasion [10,32].
The possibility that efficacy is allele-specific is being investigated
by genotyping of the parasites from breakthrough cases.
Protection against severe malaria is an important objective of
malaria vaccine efforts; however, too few cases of severe malaria
(according-to-protocol cohort: one case among FMP1/AS02 and
two among comparator recipients; intention-to-treat cohort: nine
and five cases, respectively) occurred in the present study to allow
assessment of this.
The exploratory analysis suggesting that the vaccine might have
an impact among children who do not use bednets is intriguing but
requires further critical evaluation to determine its validity. In any
case, it is clear that a malaria vaccine that targets only children
who do not use bednets is an unsupportable strategy.
FMP1/AS02 had a good safety profile and, as expected, was
more reactogenic than the comparator [20–23]. Despite this
greater reactogenicity, dropout rates were low and similar in both
groups; no dropout was attributed to an AE.
Haemoglobin levels were similar in both groups, rising
throughout the study. Although more cases of low haemoglobin
occurred in the FMP1/AS02 group, no case was judged causally
related to vaccination and all resolved spontaneously. This
observation led to an exploratory analysis to determine if there
was a significant disproportionate drop in haemoglobin between
groups. Fourteen children in the comparator group and 15 in the
FMP1/AS02 group had an observed decrease from baseline of $3
grams of Hb at least once during the study. There was no
significant difference in the risk of haemoglobin level decline to less
than 8 g/dL, the cut-off value at enrolment. Thus, as in our
previous studies [21–23], these data do not suggest a causal
relationship between FMP1/AS02 and anaemia.
The MSP-142 vaccine was clearly immunogenic, as evidenced
by the rapid, high, and prolonged antibody response. There was a
20-fold increase from day 0 to day 85 in the FMP1/AS02
recipients, whereas the comparator group experienced a slight
(11%) decrease during the same period. Although the antibody
response waned after day 85, it remained well above both baseline
and comparator for the duration of the follow-up period.
Diminishment of malaria exposure during the dry season, or
early case detection and treatment associated with the execution of
the trial, might have contributed to the gradual decline in
antibodies observed in the comparator group.
Generalizability
The study population was chosen to represent the target
population for a malaria vaccine: at risk, malaria-experienced
children living in an area of intense malaria transmission. The
primary objective of the trial being the efficacy of the vaccine,
results should be broadly generalisable to children of the
representative age bracket. As for results pertaining to the
secondary objectives, safety and immunogenicity can be general-
ised to children of this age group exposed to P. falciparum infection
in the study area as shown by a previous study [23], but may not
be generalisable to children of other age groups or living under
other transmission intensities.
Overall evidence
In conclusion, this study provides no evidence that FMP1/AS02
protects against P. falciparum malaria in an area of holoendemic
transmission, precisely where a malaria vaccine is most needed.
Because of the clearly demonstrated overall lack of efficacy in this
trial, FMP1/AS02 is no longer a promising candidate for further
development as a monovalent malaria vaccine. No previous Phase
IIb study of the FMP1 antigen has been conducted in the field and
especially in an area of holoendemic malaria transmission.
However, all the previous Phase I field studies evaluated the
safety and immunogenicity and as with our data presented found
FMP1/AS02 to be safe and highly immunogenic [21–23]. Despite
the high immunogenicity and the holoendemic malaria transmis-
sion, there was no boosting effect noted in this study. We therefore
propose that future MSP-142 vaccine development efforts should
focus on other antigen constructs and formulations.
Supporting Information
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0004708.s001 (0.04 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0004708.s002 (1.43 MB
DOC)
Acknowledgments
We thank the children and parents of Kombewa Division who participated
in the study, as well as the greater Kombewa community for their
cooperation and goodwill during this and previous activities that US Army
Medical Research Unit-Kenya has undertaken there since 1996.
The authors are grateful for the dedication and enthusiasm of the
‘‘WRP’’ Kombewa Clinic staff. We especially thank Agnes A. Onyango,
Samwel Odiwuor, William Odhiambo, Raphael Pundo, Ken Kawuondo,
Gordon Hongo, and Kurt Martin for their devotion and leadership. We
are grateful to Dr. Walter Otieno who managed the children admitted to
hospital and to Dr. Juliana Otieno who served as the LMM. We are
grateful to Sally Robinson for regulatory support and to laboratory staff at
the Department of Immunology at WRAIR, as well as to Melinda Moree,
Director of The PATH Malaria Vaccine Initiative.
We also thank the DSMB for its advice and guidance, namely Drs.
Norbert Peshu, Marcel Tanner, Clara Menendez, William Blackwelder,
and Fred Binka (Chair). We acknowledge the steadfast scientific and fiscal
support of the US Agency for International Development that has made
possible the development, cGMP manufacture, and initial clinical
evaluations of this vaccine, as well as contributing to the funding of the
present study.
At WRAIR, we appreciate the Malaria Serology Lab Staff, particularly
Genalyn Dennull and Nancy Richie. We also thank the staff at Statistics
Collaborative, Inc., especially Wasima Rida, Rui Li, Jeff Cornell, and
Kathryn Jensen for their statistical contributions.
This work has been published with the permission of the Director of
KEMRI.
Other members of the MSP-1 Malaria Vaccine Working Group are: K.
Monique Wasunna of the Kenya Medical Research Institute; Nadia
Tornieporth, Marie Claude Dubois, Els de Kock, and Alfred Tiono of
GlaxoSmithKline Biologicals, Kenneth Eckels, R. Scott Miller, Sally
Robinson, and Farhat Khan of the Walter Reed Army Institute of
Research; Rich Potter at US Army Medical Materiel and Development
Activity; and Sathit Pichyangkul, Montip Gettyacamin, and Mark Fukuda
at the Armed Forces Research Institute of Medical Sciences, Thailand.
Disclaimer: The views of the authors do not necessarily reflect the
position of the Department of the Army or the Department of Defense.
The US Government has the right to retain a nonexclusive, royalty-free
license in and to any copyright covering this paper.
Ethical review: Participants were recruited under a human use protocol
approved by, and executed in accordance with, the guidelines of the Office
of the Surgeon General, US Army; the Ethics Review Committee of the
Kenya Medical Research Institute (Kenya Ministry of Health); and the
PATH Human Subjects Protection Committee. Informed consent was
obtained from all participants in accordance with all applicable guidelines.
Malaria Vaccine Trial
PLoS ONE | www.plosone.org 10 March 2009 | Volume 4 | Issue 3 | e4708Author Contributions
Conceived and designed the experiments: BRO JOA DM FD KT JW CD
JW EMM AL LAS JM LO Mp SAR CFO JC WRB SKM EA VAS JAL
DGHJ MW. Performed the experiments: BRO JOA DM WO JS JW LO
CAH Mp SAR CFO EA VAS JAL DGHJ MW. Analyzed the data: BRO
DM FD KT CD JW EMM AL CFO EA DGHJ MW. Contributed
reagents/materials/analysis tools: BRO JOA JS JW CFO JC WRB SKM
EA VAS JAL DGHJ. Wrote the paper: BRO JOA DM FD KT JW CD JW
EMM AL LAS JM CAH CFO JC WRB EA VAS JAL DGHJ MW.
References
1. Snow RW, Craig M, Deichmann U, Marsh K (1999) Estimating mortality,
morbidity and disability due to malaria among Africa’s non-pregnant
population. Bull World Health Organ 77(8): 624–640.
2. Gallup JL, Sachs JD (2001) The economic burden of malaria. Am J Trop Med
Hyg 64(1–2 Suppl): 85–96.
3. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, et al.
(2004) Update on the clinical development of candidate malaria vaccines.
Am J Trop Med Hyg 71(2 Suppl): 239–247.
4. Alonso PL, Sacarlal J, Aponte JJ, Amanda L, Macete E, et al. (2004) Efficacy of
the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in
young African children: randomised, controlled trial. The Lancet 364:
1411–1420.
5. Alonso PL, Sacarlal J, Aponte JJ, Amanda L, Macete E, et al. (2005) Duration of
protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium
falciparum disease in Mozambican children: single-blind extended follow-up of a
randomised controlled trial. The Lancet 366: 2012–2018.
6. Diggs CL, Ballou WR, Miller LH (1993) The major merozoite surface protein as
a malaria vaccine target. Parasitol Today 9: 300–302.
7. Heppner DG, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, et al.
(2005) Towards an RTS,S-based, multi-stage, multi-antigen vaccine against
falciparum malaria: progress at the Walter Reed Army Institute of Research.
Vaccine 23(17–18): 2243–2250.
8. Blackman MJ, Dennis ED, Hirst EM, Kocken CH, Scott-Finnigan TJ, et al.
(1996) Plasmodium knowlesi: Secondary processing of the malaria merozoite
surface protein-1. Exp Parasitol 83: 229–239.
9. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA (1994) Antibodies inhibit
the protease-mediated processing of a malaria merozoite surface protein. J Exp
Med 180: 389–393.
10. Corran PH, O’Donnell RA, Todd J, Uthaipibull C, Holder AA, et al. (2004)
The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton
merozoite surface protein 1-specific antibodies is associated with resistance to
malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun
72(10): 6185–6189.
11. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, et al. (2004)
Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface
protein, PfMSP-1(19), predicts protection from malaria infection and high-
density parasitemia. Infect Immun 72: 1557–1567.
12. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, et al. (1996) Clinical
immunity to Plasmodium falciparum malaria is associated with antibodies to the 19-
kDa C-terminal fragment of the merozoites surface antigen, PfMSP-1. J Infect
Dis 173: 765–769.
13. Stowers AW, Chen L-H, Zhang Y, Kennedy MC, Zou L, et al. (2002) A
recombinant vaccine expressed in the milk of transgenic mice protects Aotus
monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci
USA 99: 339–344.
14. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, et al.
(2005) Clinical grade Plasmodium falciparum FVO MSP1-42 expressed by
Escherichia coli protects Aotus nancymai against homologous erythrocytic-stage
challenge. Infect Immun 73(1): 287–297.
15. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, et al. (1996) A
recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium
falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
Infect Immun 64: 253–261.
16. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L,
Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP,
Alpers MP (2002 Mar 15) A recombinant blood-stage malaria vaccine reduces
Plasmodium falciparum density and exerts selective pressure on parasite
populations in a phase 1–2b trial in Papua New Guinea. J Infect Dis 185(6):
820–7.
17. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N,
Anderson K, Mahakunkijcharoen Y, Martin LB, Wilson D, Elliott S, Elliott S,
Eisen DP, Weinberg JB, Saul A, Good MF (2002 Aug 24) Immunity to malaria
after administration of ultra-low doses of red cells infected with Plasmodium
falciparum. Lancet 360(9333): 610–7.
18. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, et
al. (2003) Development and pre-clinical analysis of a Plasmodium falciparum
merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol 128:
195–204.
19. Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, et al. (2004)
Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42)
formulated with novel adjuvants or with alum. Vaccine 22: 3831–3840.
20. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, et al. (2005) Phase I
safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1
asexual blood stage vaccine. Vaccine 24: 3009–3017.
21. Stoute JA, Gombe J, Withers MR, Siangla J, Mckinney D, et al. (2005) Phase 1
randomized double-blind safety and immunogenicity trial of Plasmodium
falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with
AS02A, in adults in western Kenya. Vaccine, Epub ahead of print; in press.
22. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, et al. (2006) Safety
and allele-specific immunogenicity of a malaria vaccine in Malian adults: Results
of a phase I randomized trial. PLoS Clin Trials 1(7): e34.
23. Withers MR, McKinney D, Ogutu BR, Waitumbi J, Milman JB, et al. (2006)
Safety and reactogenicity of an MSP_1 malaria vaccine candidate: A
randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials
24;1(7): e32.
24. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, et al. (1999)
Longitudinal cohort study of the epidemiology of malaria infections in an area of
intense transmission II. Descriptive epidemiology of malaria infection and
disease among children. Am J Trop Med Hyg 60(4): 641–648.
25. Beier JC, Oster CN, Onyango FK, Bales JD, Sherwood JA, et al. (1994)
Plasmodium falciparum incidence relative to entomologic inoculation rates at a site
proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg
50(5): 529–536.
26. Yoon IK, Angov E, Larson D, Heppner DG, Cummings JF, et al. (2005)
Characterization of a human reference standard for antibody to Plasmodium
falciparum merozoite surface protein 1(42). Am J Trop Med Hyg 72(6): 714–718.
27. World Health Organization (2000) Severe falciparum malaria. Trans R Soc
Trop Med Hyg 94, supplement 1: S1–90.
28. al-Yaman F, Genton B, Kramer KJ, Taraika J, Chang SP, et al. (1995) Acquired
antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents
of a highly endemic area of Papua New Guinea. Trans R Soc Trop Med Hyg
89: 555–559.
29. al-Yaman F, Genton B, Kramer KJ, Chang SP, Hui GS, et al. (1996) Assessment
of the role of naturally acquired antibody levels to Plasmodium falciparum
merozoite surface protein-1 in protecting Papua New Guinean children from
malaria morbidity. Am J Trop Med Hyg 54: 443–448.
30. Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, et al. (1996) Natural
immune response to the C-terminal 19-kilodalton domain of Plasmodium
falciparum merozoite surface protein 1. Infect Immun 64: 2716–2723.
31. Braga EM, Barros RM, Reis TA, Fontes CJ, Morais CG, et al. (2002)
Association of the IgG response to Plasmodium falciparum merozoite protein (C-
terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon
region. Am J Trop Med Hyg 66: 461–466.
32. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ (1997) Antibodies
that inhibit malaria merozoite surface protein-1 processing and erythrocyte
invasion are blocked by naturally acquired human antibodies. J Exp Med
186(10): 1689–1699.
Malaria Vaccine Trial
PLoS ONE | www.plosone.org 11 March 2009 | Volume 4 | Issue 3 | e4708